LSIPR 50: Daniela Verthelyi—Safety first

According to Daniela Verthelyi of the US Food and Drug Administration (FDA), the development of therapeutic proteins and peptides has improved the lives of countless patients, but there are still numerous challenges ahead, including those relating to bioavailability and immunogenicity.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Semaglutide patent battle heats up with new blow for Novo in India

6 February 2026 A Delhi High Court ruling signals more bad news for the Danish pharma giant in the same week that it lost nearly $50 billion in value.

Americas

LSPN Awards USA returns for second year—with new categories

3 February 2026 Nominations are open for the Life Sciences Patent Network's 2026 awards in Boston, including six new categories and winners selected by leading industry experts.

Americas

Sanofi suffers setback in insulin monopoly dispute

29 January 2026 A judge has allowed antitrust claims against the pharma giant to move forward, finding that it plausibly used bundled rebates and patent abuse to extend its insulin monopoly, though one allegation was dismissed.

More features

Semaglutide patent battle heats up with new blow for Novo in India

Wilson Sonsini senior counsel moves to a rival firm

INTA: ‘Davos of IP’ will take London meeting to a ‘different level’

Nine-partner litigation team leaves Winston & Strawn

LSPN Awards USA returns for second year—with new categories

Crowell adds tech partner with in-house and private practice expertise

Winston & Strawn and Taylor Wessing UK seal ‘powerhouse’ merger

Sanofi suffers setback in insulin monopoly dispute

LSIPR 50: Daniela Verthelyi—Safety first

More on this story

Editor's picks

Editor's picks

More features